Large-Scale Proteomics-Based Risk Score for the Prediction of Incident Cardio-Kidney-Metabolic Disease Risk
Circulation: Genomic and Precision Medicine · 2025-10 · 18 (5)
DOI: 10.1161/circgen.124.005125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation: Genomic and Precision Medicine, 2025-10. Verfasst von Adithya K Yadalam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.K.Y., A.C.R., L.S.S., A.A.Q., Y.V.S.). Hauptthemen laut MEDLINE: Proteomics, Cardiovascular Diseases, Metabolic Diseases, Kidney Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Cardio-kidney-metabolic (CKM) disease represents a significant public health challenge. While proteomics-based risk scores (ProtRS) enhance cardiovascular risk prediction, their utility in improving risk prediction for a composite CKM outcome beyond traditional risk factors remains unknown. METHODS: We analyzed 23 815 UK Biobank participants without baseline CKM disease, defined by International Classification of Diseases -Tenth Revision codes as cardiovascular disease (coronary artery disease, heart failure, stroke, peripheral arterial disease, atrial fibrillation/flutter), kidney disease (chronic kidney disease or end-stage renal disease), or metabolic disease (type 2 diabetes or obesity). The sample was randomly divided into ProtRS training (70%, n=16 671) and validation (30%, n=7144) cohorts. A least absolute shrinkage and selection operator-based Cox regression model of 2913 Olink-based proteins was utilized to develop the ProtRS in the training cohort. We then assessed the association of the ProtRS with incident CKM disease risk in the validation cohort with competing-risk regression after adjusting for traditional risk factors and evaluated its ability to discriminate incident CKM disease risk with C-indices. RESULTS: The study sample had a mean age of 56.1 years; 44% were men, and 94% were White. Over a median follow-up of 13.5 years, 3235 and 1407 incident CKM disease events occurred in the training and validation cohorts, respectively. A ProtRS based on the weighted sum of the 238 least absolute shrinkage and selection operator-selected proteins was significantly associated with incident CKM disease risk (subdistribution hazard ratio per 1-SD, 1.87 [95% CI, 1.73–2.03]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Emory University School of Medicine, Atlanta, GA (A.K.Y., A.C.R., L.S.S., A.A.Q., Y.V.S.).
- Emory Clinical Cardiovascular Research Institute, Atlanta, GA (A.K.Y., A.C.R., L.S.S., A.A.Q.).
- Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA (C.L., Q.H., Y.V.S.).
- Atlanta Veterans Affairs Healthcare System, Decatur, GA (Y.V.S.).
ORCID-Profile: Adithya K Yadalam, Chang Liu, Qin Hui, Alexander C Razavi, Laurence S Sperling, Arshed A Quyyumi, Yan V Sun
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Yadalam, A. K., Liu, C., Hui, Q., Razavi, A. C., Sperling, L. S., Quyyumi, A. A., & Sun, Y. V. (2025). Large-Scale Proteomics-Based Risk Score for the Prediction of Incident Cardio-Kidney-Metabolic Disease Risk. Circulation: Genomic and Precision Medicine, 18(5). https://doi.org/10.1161/circgen.124.005125
Vancouver
Yadalam AK, Liu C, Hui Q, Razavi AC, Sperling LS, Quyyumi AA, et al. Large-Scale Proteomics-Based Risk Score for the Prediction of Incident Cardio-Kidney-Metabolic Disease Risk. Circulation: Genomic and Precision Medicine. 2025;18(5). doi:10.1161/circgen.124.005125
BibTeX
@article{Yadalam2025,
author = {Yadalam, Adithya K and Liu, Chang and Hui, Qin and Razavi, Alexander C and Sperling, Laurence S and Quyyumi, Arshed A and Sun, Yan V},
title = {Large-Scale Proteomics-Based Risk Score for the Prediction of Incident Cardio-Kidney-Metabolic Disease Risk},
journal = {Circulation: Genomic and Precision Medicine},
year = {2025},
volume = {18},
number = {5},
doi = {10.1161/circgen.124.005125}
}
EUVIMED